SAHA attenuates Takotsubo-like myocardial injury by targeting an epigenetic Ac/Dc axis  

作　　者：Ishant Khurana Scott Maxwell Simon Royce Prabhu Mathiyalagan Tom Karagiannis Nadia Mazarakis Jitraporn Vongsvivut Harikrishnan K.N. Jun Okabe Keith Al-Hasani Chrishan Samuel Assam El-Osta 

机构地区：[1]Human Epigenetics Program,Department of Diabetes,Central Clinical School,Monash University,Melbourne,VIC,Australia [2]Cardiovascular Disease Program,Monash Biomedicine Discovery Institute and Department of Pharmacology,Monash University,Clayton,VIC,Australia [3]Infrared Microspectroscopy Beamline,ANSTO-Australian Synchrotron,Clayton,VIC,Australia [4]Department of Medicine and Therapeutics,The Chinese University of Hong Kong(CUHK),Hong Kong SAR,Hong Kong Institute of Diabetes and Obesity,CUHK,Hong Kong SAR,Prince of Wales Hospital,Li Ka Shing Institute of Health Sciences,CUHK,Shatin,Hong Kong,China [5]University College Copenhagen,Faculty of Health,Department of Technology,Biomedical Laboratory Science,Copenhagen,Denmark

出　　处：《Signal Transduction and Targeted Therapy》2021年第5期1429-1432,共4页信号转导与靶向治疗（英文）

基　　金：A.E-O.dedicates this article to his late grandmother.Professor Sam El-Osta is a National Health and Medical Research Council(NHMRC)Senior Research Fellow(1154650);Funded by NSFC(81561128017)and NHMRC(1113188)International Joint Programme.

摘　　要：Dear Editor,Takotsubo syndrome(TS)is a stress-induced non-ischaemic cardiomyopathy that is more common in women,but is associated with higher morbidity and mortality in males.Also known as broken-heart syndrome,TS is characterised by transient left ventricular(LV)dysfunction independent of obstructive coronary artery disease.TS is a polygenic condition and nowhere is this more evident than the use of positive inotropes,such as isoprenaline(ISO)in pre-clinical models.1 There is no standard therapy for broken-heart syndrome because the mechanisms underlying the condition remain unknown.Furthermore,there is no consensus on predisposition for Takotsubo2 and our goal was to better understand the regulatory mechanism as a first step towards improved treatment plans.Suberanilohydroxamic acid or SAHA,a drug approved for cancer treatment by the US Food and Drug Administration has previously been shown to improve cardiopulmonary function.3 We tested the hypothesis that the cardioprotective benefit of SAHA in a pre-clinical model of Takotsubo is conferred by an epigenetic acetylation/deacetylation(Ac/Dc)axis.

关 键 词：SAHA TAKOTSUBO protective 

分 类 号：R542.2[医药卫生—心血管疾病]